For: | Saito A, Yoshida H, Nishikawa T, Yonemori K. Human epidermal growth factor receptor 2 targeted therapy in endometrial cancer: Clinical and pathological perspectives. World J Clin Oncol 2021; 12(10): 868-881 [PMID: 34733610 DOI: 10.5306/wjco.v12.i10.868] |
---|---|
URL: | https://www.wjgnet.com/2220-315X/full/v12/i10/868.htm |
Number | Citing Articles |
1 |
Turgut Keles, Gökçe Seyhan, Zekeriya Biyiklioglu, Kübra Kolci, Rengin Reis, Burak Barut. Dendritic, Water‐Soluble, and Nonaggregated Axially Substituted Silicon Phthalocyanine as Potential Endometrial Anticancer Agent. Applied Organometallic Chemistry 2024; doi: 10.1002/aoc.7699
|
2 |
Takuya Yoshimura, Shotaro Higashi, Sohsuke Yamada, Hirotsugu Noguchi, Mitsuharu Nomoto, Hajime Suzuki, Takayuki Ishida, Hirotaka Takayama, Yuka Hirano, Masaru Yamashita, Akihide Tanimoto, Norifumi Nakamura. PCP4/PEP19 and HER2 Are Novel Prognostic Markers in Mucoepidermoid Carcinoma of the Salivary Gland. Cancers 2021; 14(1): 54 doi: 10.3390/cancers14010054
|
3 |
Nora Diéguez-Martínez, Sergio Espinosa-Gil, Guillermo Yoldi, Elisabet Megías-Roda, Idoia Bolinaga-Ayala, Maria Viñas-Casas, Gokhan Gorgisen, Inés Domingo-Ortí, Héctor Pérez-Montoyo, Jose R. Bayascas, Eva Colas, Xavier Dolcet, Jose M. Lizcano. The ERK5/NF-κB signaling pathway targets endometrial cancer proliferation and survival. Cellular and Molecular Life Sciences 2022; 79(10) doi: 10.1007/s00018-022-04541-6
|
4 |
Yidong Ge, Xiaoqi Ni, Jingyun Li, Meng Ye, Xiaofeng Jin. Roles of estrogen receptor α in endometrial carcinoma (Review). Oncology Letters 2023; 26(6) doi: 10.3892/ol.2023.14117
|
5 |
S. Koppikar, A. Oaknin, K. Govind Babu, D. Lorusso, S. Gupta, L.-Y. Wu, W. Rajabto, K. Harano, S.-H. Hong, R.A. Malik, H. Strebel, I.M. Aggarwal, C.-H. Lai, T. Dejthevaporn, S. Tangjitgamol, W.F. Cheng, W.Y. Chay, D. Benavides, N.M. Hashim, Y.W. Moon, M. Yunokawa, T.D. Anggraeni, W. Wei, G. Curigliano, A. Maheshwari, U. Mahantshetty, S. Sheshadri, S. Peters, T. Yoshino, G. Pentheroudakis. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with endometrial cancer. ESMO Open 2023; 8(1): 100774 doi: 10.1016/j.esmoop.2022.100774
|
6 |
Malames M. Faisal, Marwa M. Shakweer, Ghada Refaat, Khaled S. Mohammed, Tarek I. ElMallawy, Magda H. Nasreldin, Laila M. Farid, Mariam B. Abouelkhair. Analysis of human epidermal growth factor receptor 2 immunohistochemical expression in high-grade endometrial carcinomas and its association with variable clinical outcomes. Egyptian Journal of Pathology 2023; 43(2): 119 doi: 10.4103/egjp.egjp_27_23
|
7 |
Jean-Christophe Currie, Michel Demeule, Cyndia Charfi, Alain Zgheib, Alain Larocque, Bogdan Alexandru Danalache, Amira Ouanouki, Richard Béliveau, Christian Marsolais, Borhane Annabi. The Peptide-Drug Conjugate TH1902: A New Sortilin Receptor-Mediated Cancer Therapeutic against Ovarian and Endometrial Cancers. Cancers 2022; 14(8): 1877 doi: 10.3390/cancers14081877
|
8 |
Bradley Corr, Casey Cosgrove, Daniel Spinosa, Saketh Guntupalli. Endometrial cancer: molecular classification and future treatments. BMJ Medicine 2022; 1(1): e000152 doi: 10.1136/bmjmed-2022-000152
|
9 |
Hiroshi Yoshida, Chiharu Mizoguchi, Ayumi Saito, Rui Kitadai, Kasumi Yamamoto, Tadaaki Nishikawa, Tomoyasu Kato, Kan Yonemori. Discordances in expression of human epidermal growth factor receptor 2 between primary and metastatic uterine carcinosarcoma: A proposal for HER2-targeted therapy specimen selection. Annals of Diagnostic Pathology 2023; 65: 152150 doi: 10.1016/j.anndiagpath.2023.152150
|